All treatments
Treatment
Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase II and Phase III (Integrated)
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
This study looks at a new inhaled medicine for people with high blood pressure in their lungs, linked to a lung scarring condition. It aims to see if the medicine is safe, well-tolerated, and helpful over a long time, checking for side effects and improvements in walking and breathing.
For: Pulmonary Hypertension Associated with Interstitial Lung DiseaseSpain · Italy · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension
This study is testing a new inhaled powder medicine for a lung condition called pulmonary arterial hypertension (PAH). Researchers want to see if it helps patients and if it's safe. It compares different strengths of the new medicine against a dummy powder.
For: Pulmonary Arterial HypertensionBelgium · Italy · Spain